Infectious Dis. Medical News about Costs and Cost Analysis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Complementing the net benefit approach: A new framework for Bayesian cost-effectiveness analysis
International Journal of Technology Assessment in Health Care, 11/05/09

Hernande MAN et al. – An application with real data is included to illustrate the analysis. Decision–making measures such as the incremental cost–effectiveness ratio, incremental net–benefit, and cost–effectiveness acceptability curves, can also be defined under the new framework.

<< Previous
Handling uncertainty in economic evaluations of patient level...

Next >>
Effect of Procalcitonin-Guided Treatment in Patients with...

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 83%

Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study
Modern Rheumatology, 10/15/09 Relevance Score: 83%

Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer
American Journal of Clinical Oncology, 10/06/09 Relevance Score: 83%

Paediatric Robotic Surgery in Clinical Practice: A Cost Analysis
European Journal of Pediatric Surgery, 10/16/09 Relevance Score: 82%

A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
PharmacoEconomics, 10/12/09 Relevance Score: 82%